Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glucose transporter 5 (GLUT5)
- Target
- GLUT5
- Molecular classification
- Transporter, Major facilitator superfamily (MFS) transporter, Sugar transporter
01
Overview
Glucose transporter 5 (GLUT5), also known as SLC2A5, is a membrane protein belonging to the major facilitator superfamily (MFS) of transporters. Unlike other GLUT family members, GLUT5 exhibits a high specificity for fructose rather than glucose and is predominantly expressed in the small intestine, kidney, and sperm. It plays a crucial role in the absorption of dietary fructose from the intestinal lumen into enterocytes. Structurally, GLUT5 comprises twelve transmembrane domains forming two bundles and contains regions responsible for high-affinity fructose binding and transport. The transporter has been implicated in diseases linked to altered fructose metabolism and is increasingly investigated as a target in cancer and metabolic disorders[1][5][2][3].
- Other names
- Hexose transporter GLUT5SLC2A5solute carrier family 2 member 5
02
Mechanism of action
Inhibition of fructose transport by blocking or modulating the GLUT5 transporter
03
Biological functions
Fructose transportDietary fructose absorptionCellular fructose uptake
04
Disease associations
CancerMetabolic diseaseOther (implicated in fructose-linked pathologies such as diabetes, obesity, and nonalcoholic fatty liver disease)
05
Safety considerations
The selective inhibition of GLUT5 could potentially affect normal fructose absorption, leading to gastrointestinal side effects or metabolic disturbances. Long-term effects of targeting this transporter in humans remain unknown[1].
06
Interacting drugs
There are currently no approved drugs specifically targeting GLUT5; research probes and inhibitor molecules for GLUT5 are under investigation[1].
07
Biomarkers
Overexpression of GLUT5 is considered a biomarker for certain cancers (e.g., breast cancer) and diseases related to altered fructose metabolism[1].
Beyond the preview
Go deeper on Glucose transporter 5 (GLUT5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glucose transporter 5 (GLUT5).